(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/063885 A1

(51) International Patent Classification:
A61K 47/64 (2017.01) *A61K 47/60* (2017.01)
A61K 47/68 (2017.01)

(21) International Application Number:
PCT/EP2021/076180

(22) International Filing Date:
23 September 2021 (23.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20197699.0 23 September 2020 (23.09.2020) EP
21167124.3 07 April 2021 (07.04.2021) EP

(71) Applicant: **ABLEVIA BIOTECH GMBH** [AT/AT]; Maria-Jacobi-Gasse 1, 1030 Wien (AT).

(72) Inventors: **SMRZKA, Oskar**; c/o Ablevia biotech GmbH, Maria-Jacobi-Gasse 1, 1030 Wien (AT). **WANKO, Bettina**; c/o Ablevia biotech GmbH, Maria-Jacobi-Gasse 1, 1030 Wien (AT).

(74) Agent: **SONN PATENTANWÄLTE OG**; Riemergasse 14, 1010 Wien (AT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT

(57) Abstract: The present invention provides a compound for the sequestration of undesirable anti-polyethylene glycol (PEG) antibodies interfering with therapy by PEGylated active agents (such as PEGylated enzymes or antibodies) in a patient. The compound comprises an inert biopolymer scaffold and one or more PEG chains. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more anti-PEG antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with a PEGylated active agent.

WO 2022/063885 A1